Business context and reporting period
The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2017—not a filing identified as Bio Green Med Solution, Inc. Cyclacel is a clinical-stage biopharmaceutical company developing cancer therapies. Its principal programs include CYC065, a CDK inhibitor in a Phase 1 trial; sapacitabine with seliciclib in a Phase 1/2 study; and completion of analysis of the Phase 3 SEAMLESS AML study.
Financial results and liquidity
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | $0 | $222,000 | $0 | $361,000 |
| Research and development expense | $1.222 million | $2.637 million | $2.534 million | $5.136 million |
| General and administrative expense | $1.267 million | $1.345 million | $2.648 million | $2.729 million |
| Operating loss | $2.489 million | $3.760 million | $5.182 million | $7.504 million |
| Net loss | $2.187 million | $2.965 million | $3.742 million | $6.006 million |
| Net loss applicable to common shareholders | $2.237 million | $3.015 million | $3.842 million | $6.106 million |
| Basic and diluted loss per share | $0.50 | $1.01 | $0.88 | $2.05 |
Amounts are shown as losses where applicable. Revenue consisted of grant revenue in the 2016 periods; the company reported no grant revenue in 2017. As a development-stage company with no product revenue, operating margins are not meaningful.
- Cash and liquidity: Cash and cash equivalents were $13.591 million at June 30, 2017, down from $16.520 million at December 31, 2016. Working capital was $11.732 million. Current liabilities were $4.319 million; total liabilities were $4.447 million. No debt is separately reported on the balance sheet.
- Cash flow: Six-month operating cash use was $4.011 million, investing cash use was $2,000, and financing provided $962,000. Cash declined by $2.929 million during the period.
- Equity: Stockholders’ equity was $11.636 million at June 30, 2017; accumulated deficit was $338.780 million. The company had 4,439,947 common shares outstanding at quarter-end.
Material changes versus the prior comparable period
- Six-month operating expenses fell 34% to $5.182 million, principally because R&D expense decreased 51% as SEAMLESS clinical sites were closed. G&A expense was broadly flat.
- Net loss narrowed to $3.742 million for the first half of 2017 from $6.006 million in 2016. The decrease reflected lower operating expenses and higher other income, partly offset by the absence of grant revenue and lower tax benefits.
- Six-month other income was $866,000 versus $379,000 in 2016. It included $879,000 of income under an asset purchase agreement with Life Technologies; the amount and timing of future income are uncertain. Foreign exchange results moved from a $318,000 gain to a $43,000 loss.
- Cash fell by $2.929 million from year-end despite $1.063 million of net proceeds from common stock sales under the company’s at-the-market program.
Outlook, risks and notable items
- Management stated that June 30 cash, together with approximately $13.8 million of net proceeds from a July 2017 securities offering, was expected to fund operations and capital requirements through the end of 2019. The filing says funding beyond 2019 depends on raising additional capital; there is no assurance it will be available on acceptable terms.
- The July offering included common stock, warrants and convertible Series A preferred stock. After closing, holders converted 7,613 preferred shares into 3,806,500 common shares. As of August 8, 2017, 11,400,447 common shares and 1,259 Series A preferred shares remained outstanding, indicating significant potential dilution.
- Management expected 2017 R&D expense to decrease from 2016 levels as SEAMLESS sites close, while G&A expense was expected to remain relatively flat. Any SEAMLESS regulatory submissions depend on final clinical data. The company warned that it cannot fund full development and commercialization of its candidates with current resources and may need to reduce programs, partner assets or raise further capital.
- Drug candidates require regulatory approval, and delayed or unsuccessful trials or inability to obtain financing could materially harm the business. The company also relies on UK R&D tax credits, whose amount depends on qualifying expenditures, and does not expect prior government grant funding to continue reliably.
- A further $10.0 million in aggregate milestone payments may be payable under the Daiichi Sankyo sapacitabine license if specified milestones are achieved. The filing reports no legal proceedings and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer identity: the source filing names Cyclacel Pharmaceuticals, Inc., contrary to the request metadata naming Bio Green Med Solution, Inc.
- Review the final SEAMLESS results and whether management pursues regulatory submissions, as these affect future spending and prospects.
- Assess the cash runway assumptions, including the July financing proceeds, expected R&D tax credits and planned clinical costs.
- Review dilution from the July offering, warrant terms, preferred-stock conversions and the remaining potential share issuance.
- Evaluate the sustainability of the $879,000 Life Technologies-related income and the conditions attached to the Daiichi Sankyo milestones.